Exelixis, Inc.

Ladies and gentlemen, thank you for standing by, and welcome to the Excel Exist Q1 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone. Please be advised that today's conference is being recorded. If you require any further assistance, please press star 0. I would now like to hand the conference over to your speaker, Ms. Susan Hubbard, Executive Vice President of Public Affairs and Investor Relations. Please go ahead.

Thank you, Cherie, and thank you all for joining us for the Exalexa's first quarter 2022 financial results conference call. Joining me on today's call are Mike Morrissey, our President and CEO, Chris Center, our Chief Financial Officer, PJ Haley, our Executive Vice President of Commercials, Vicki Goodman, our Chief Medical Officer, and Peter Lamb, our Chief Scientific Officer, who will together review our progress for the first quarter 2022 and in March 31st, 2022. During the call today, we will refer to financial measures not calculated according to generally accepted accounting principles. Please refer to today's press release, which is posted on our website, for an explanation of our reasons for using such non-GAAP measures, as well as tables deriving these measures from our GAAP results. During the course of this presentation, we will be making forward looking statements regarding future events and the future performance of the company. This includes statements about possible developments regarding discovery, product development, regulatory, commercial, financial, and strategic matters. Actual events or results could, of course, differ materially. We refer you to the documents we file from time to time with the SEC, which under the heading Risk Factors, identify important factors that could cause actual results to differ materially from those expressed by the company verbally and in writing today, including without limitation, risks and uncertainties related to product commercial success, market competition, regulatory review and approval processes, conducting clinical trials, compliance with applicable regulatory requirements, our dependence on collaboration partners, and the level of costs associated with discovery, product development, business development, and commercialization activities. And with that, I'll now turn the call over to Mike.

All right. Thank you, Susan, and thanks to everyone for joining us on the call today. ExoLux has had a strong first quarter 2022 across all components of our business. We continue to grow the Cabo's antigen franchise and advance a diversified pipeline of clinical and discovery programs while focusing on important upcoming milestones, including top-line results for ongoing pivotal trials, ASCO preparation, and the Cabo and the trial starting on May 16th. We'll keep our prepared remarks short today so we can address your important questions. Key highlights from Q1 include first, the Cabo Zantanet business continues to grow and generate the funds to advance our portfolio of next generation therapies for oncology. Cabo Medics maintained its status as the leading TKI for RCC. The Cabo franchise grew 37% year over year compared to first quarter 2021, marking its sixth consecutive quarter of growth. Second, our emerging bi-coastal development team is focused on expanding potential CAVO indications with numerous expected top-line results for important COSMIC and CONTACT pivotal trials and advancing our growing pipeline of clinical compounds, including XL092, XB002, XL102, and XL114, including the upcoming initiation of the pivotal trial program for XL092. Third and finally, our drug discovery network of internal and collaborative efforts along with extensive business development activities across both small molecule and biologic platforms continues to advance at a rapid pace with the selection of up to five new development candidates expected in 2022. So with that, please see our press release issued an hour ago for our first quarter financial results and an extensive list of key corporate milestones achieved in the quarter. I'll now turn the call over to Chris.